| Jul 25 |
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
|
| Jul 25 |
Sanofi’s immunology bet starts to pay off
|
| Jul 25 |
Sanofi 2024 Q2 - Results - Earnings Call Presentation
|
| Jul 25 |
Sanofi: Q2 Earnings Snapshot
|
| Jul 25 |
Sanofi Non-GAAP EPS of €1.73, revenue of €10.74B; raises FY24 EPS outlook
|
| Jul 25 |
Sanofi lifts 2024 profit forecast on strength in Dupixent, new products
|
| Jul 25 |
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
|
| Jul 24 |
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
|
| Jul 23 |
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
|
| Jul 23 |
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
|
